Sydbank: Patent case against Genmab is a disturbance, not a threat
The patent suit filed by Germany’s Morphosys against Genmab and Janssen will not pose a threat to oncology hope Darzalex, says an analyst from Sydbank. But a settlement agreement might be on the cards.
BY ELIZABETH MØNSTED JOHANSEN
Danish biotech company Genmab has become accustomed to announcing new regulatory advanced and positive trial data. But for the first time in a while, the announcement published by the company in the beginning of the week was not of a positive nature.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Biotech company sues Genmab
For abonnenter
EMA favors Genmab’s oncology star
For abonnenter
